Pfizer’s Pride-And-Joy Pain Drug Lyrica Slips In Two New Phase III Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
One failed study tested Lyrica in a subset of difficult-to-treat patients in the approved indication of diabetic neuropathy, while another explored its use in neuropathic pain related to HIV.